Tech Company Financing Transactions
Laronde Funding Round
Laronde closed a $440 million Series B venture capital round on 8/31/2021. Backers included BlackRock, Canada Pension Plan Investment Board and Federated Kaufmann Funds.
Transaction Overview
Company Name
Announced On
8/31/2021
Transaction Type
Venture Equity
Amount
$440,000,000
Round
Series B
Investors
Proceeds Purpose
Capital infusion will enable the build out of Laronde's Endless RNA technology platform and large-scale development capabilities, advancing multiple eRNA programs in parallel
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
55 Cambridge Pkwy. 800E
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Laronde is building a company fueled by our modular Endless RNA (eRNA) platform, which will be supported by a large-scale digital and manufacturing infrastructure with the bold vision of 100 new medicines within the next decade. With eRNA, we're making new therapeutics that will become essential medicines of the future.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Diego Miralles
Chief Operating Officer
Tej Pavoor
Chief Scientific Officer
Jesper Gromada
Chief Technical Officer
Vadim Dudkin
VP - R & D
Jennifer Nelson
Browse more venture capital transactions:
Prev: 8/31/2021: Jifiti venture capital transaction
Next: 8/31/2021: Alpaca venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs